2 research outputs found
Aprepitant in refractory pruritus of systemic lymphoproliferative disorders
araneoplastic pruritus represents a frequent symptom in the debut or progression of lymphoproliferative disorders. It affects approximately 30% of patients with Hodgkin lymphoma and 15% of patients with non-Hodgkin lymphoma.1 Aprepitant has shown promising results in the treatment of refractory pruritus of primary cutaneous T-cell lymphomas (CTCL)